Interview: Qiu Jiazhou – MD Chairman, H-Guard, China
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
Address: Rongjing Dong Street, Beijing Economic and Technological Development Zone Zip: 100176
Tel: -111549.584415584
Web: http://www.biotechplc.com/
BioteQ Bio-Pharmaceutical Co., Ltd. was established in August 2000, China and Cuba in the field of biotechnology, the highest level, the largest investment cooperation projects, to research and development and production of the treatment of malignant tumors, the source resistance, monoclonal antibodies and vaccines undertake the major projects of the National High-Tech Research and Development Plan, the national high-tech industrialization demonstration project for the main direction.
100 Thai Biological Pharmaceutical has China’s first world-class antibodies humanized technology platform, represents a core technology of the international bio-pharmaceutical development and direction of the mainstream. The company designed and built the production line of China’s first fully automated large-scale mammalian cell culture, which is currently the largest, most comprehensive facilities, the most technologically advanced large-scale cell culture technology platform.
The Biological Pharmaceutical Baitai successfully developed China’s first personal humanized monoclonal antibody drug – Taixinsheng nimotuzumab the drug in April 2005 Biology I class drug certificate issued by the State Food and Drug Administration , fill our humanized monoclonal antibody drugs blank. The Taixinsheng ® can specifically target the tumor cells to targeted therapies in killing tumor cells without damaging normal tissue, and represent the latest developments in the direction of the field of cancer treatment. Clinical studies have shown that Taixinsheng ® single-agent or combined radiotherapy and chemotherapy for head and neck cancer, colorectal cancer, glioma, non-small cell lung cancer efficacy, significant side effects is low, with high clinical value.
Same time the Biological Pharmaceutical Baitai actively carry out international technical transformation, is committed to nurturing the capability of independent innovation, new drugs are being developed, including the EGF vaccine for the treatment of cancer, psoriasis and rheumatoid arthritis, a humanized anti-CD6 single anti for reversal of organ transplant rejection anti-CD3 mAb.
The Biological Pharmaceutical development Baitai target large modern biopharmaceutical company, to improve antibody drug research and development capabilities and production levels, to improve the health of the people for the purpose, internationalization, industrialization, standardization, the scale of the operation mode, is committed to the latest achievements of the development of biotechnology into the cause of the health of the 21st century, and continuous dedication to the community is the most advanced, most excellent antibody drugs, witnessed the rise of China’s life sciences and biomedicine with you!
Research and Development
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
Simon, you established Glory Medical back in 1998. What was the main rationale behind this significant decision? “We already have operations in Sri Lanka and Pakistan, and are exploring projects…
Dr. Chen Hao is the CEO and founder of the promising startup Imsight, the only company focusing on medical imaging analysis using Artificial Intelligence technology in the Greater Bay Area.…
Alex Wang Yimin, founder and CEO of SONTU Medical Imaging, shares the exciting story of SONTU’s development since 2009, their significant investment into R&D and various international certifications like the…
Dr. Lu Xianping is the founder and now Chairman and CEO of one of China’s few truly innovative biotech companies, ChipScreen BioSciences Co. In this exciting interview, he shares the…
Scott Liang, president of Apex (Guangzhou) Tools and Orthopedics discusses the company’s strong positioning on the Chinese medtech market, current strategic priorities, and what differentiates Apex from its competitors. As…
Dami Qiu, founder and CEO of EMP, shares her personal story of how she decided to establish EMP two decades ago, the market opportunities in ultrasound medical equipment in China,…
In this unique interview, Dr. David Peng, CEO of Medical Excellence International (China), shares the company´s foundations, its key milestones as well as its two unique membership programs. He further…
Sheng Sitong, founder and CEO of gene sequencing device company, Considerin Group (formerly HYK Gene), discusses Considerin’s rapid expansion and the development of precision medicine in China. Mr. Sheng, could…
Yuan Qing, President of the Shenzhen Life Science and Biotechnology Association, shares his insights on the characteristics of the life sciences environment in Shenzhen, the importance of the sectors as…
Guangdong province and neighbouring Hong Kong have long been fundamental to China’s metamorphosis into an economic superpower. Notable as one of the country’s most open and dynamic regions, the Pearl…
One of the more eye-catching and ambitious initiatives to come out of last March’s National People’s Congress, Premier Li Keqiang’s grand vision for the cultivation of a globally competitive cluster…
See our Cookie Privacy Policy Here